Vitamin A With BCG Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168597|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Mortality Morbidity||Drug: Vitamin A||Phase 4|
Vitamin A deficiency is common in low-income countries. Vitamin A supplementation to children above 6 months of age reduces all-cause mortality with 23 % to 30 %. Studies on vitamin A supplementation in infants younger than 6 months of age have reported inconsistent effects on mortality. Studies providing supplementation between 1 and 5 months of age have found no effect or even a negative effect. However, the only two studies of supplementation at birth, both conducted in Asia, showed substantial significant reductions in infant all-cause mortality.
The beneficial effect of neonatal vitamin A supplementation may be a result of correcting the congenital vitamin A deficiency resulting from maternal vitamin A deficiency. On the other hand, it has been speculated that the beneficial effect of vitamin A supplementation given at birth may in part be explained by a synergistic effect of vitamin A supplementation and BCG vaccination given at the time of birth.
The protective effect on mortality of vitamin A supplementation given at birth needs to be confirmed in an African population. Furthermore, none of the two previous studies have reported data on vaccination status of the included infants.
In this study, the effect on mortality and morbidity of given vitamin A supplementation simultaneously with BCG vaccination at birth to normal birth weight infants will be investigated in an African population. Furthermore, the effects of vitamin A supplementation will be evaluated with respect to effect on growth, the response to BCG vaccination, infant vitamin A status and infant cytokine profile. Furthermore the effect on specific diseases such as malaria, measles and rotavirus infections. The mechanisms behind the effects of vitamin A will be evaluated.
We will include 4,800 normal birth weight infants (> 2500 g) infants randomized to 50,000 IU of vitamin A or placebo given simultaneously with BCG vaccine. The study take place in Guinea-Bissau, West Africa. The study area consists of five districts in the capital of Guinea-Bissau. The Bandim Health Project has been working in the study area for almost 25 years, and a demographic surveillance system has been established and functioned for many years.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||4800 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?|
|Study Start Date :||August 2002|
|Actual Primary Completion Date :||November 2013|
- Adverse effects
- Tuberculin reaction
- BCG scarring
- Vitamin A status
- Cytokine responses
- All primary and secondary outcomes will be analysed for interactions between vitamin A and sex and last vaccine received
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168597
|Bandim Health Project, Apartado 861|
|Principal Investigator:||Peter Aaby, DMSc||Bandim Health Project|